Microbot Medical Receives Several New Patent Approvals Across US, Japan, China And Canada, Further Strengthening Its Global IP Portfolio

Microbot Medical Inc. has received multiple patent approvals in the U.S., Japan, China, and Canada, enhancing its global intellectual property portfolio to 44 issued patents and 49 pending applications. The company is focused on advancing the commercialization of its LIBERTY® Endovascular Robotic System in both domestic and international markets while pursuing a CE Mark. These developments are part of Microbot's strategy to protect its innovations and support future market expansion.